secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015549
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma Q2 net loss widens to $13.9M; cash runway into 2025
----------------------------------------------------------------

- Net loss of $13.9M ($0.55 per share) vs $10.7M ($0.43) in Q2 2021.
- Cash and equivalents $139.8M as of June 30, down from $166.0M at Dec 31, 2021; expected to fund operations into 2025.
- R&D expenses $8.7M (up from $6.0M); G&A $5.4M (up from $4.9M).
- TERN-701 Phase 1 CML trial initiated in China; TERN-601 IND-enabling on track for Phase 1 obesity trial in 2023.
- TERN-501 Phase 2a DUET NASH trial initiated; top-line data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/0000950170-22-015549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022015549/tern-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer